HC Wainwright & Co. Reiterates Buy on Prime Medicine, Maintains $8 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $8 price target.
Last updated: 2026-11-19 02:28:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Prime Medicine, Inc. (PRME) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $3.84, with a market capitalization of $934.34M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.67 to $5.91. This page covers its latest market performance, valuation, price trends and company information.
$934.34M | |
$3.81 | |
$4.28 | |
$3.79 | |
$3.84 | |
3.70M | |
4.60M | |
-- | |
$5.91 | |
$2.67 | |
-- | |
2026-09-30 |
Prime Medicine, Inc. (PRME) last closed at $3.84 as of 2026-11-19 00:47:00, up 0.66% ($0.02) from the previous close of $3.84.
During the latest regular trading session, PRME traded between $3.79 and $4.28, with a volume of 3.70M shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Prime Medicine, Inc. (PRME) moved from $4.30 to $3.84, representing a decline of 10.81% ($0.46).
The stock traded between $3.73 and $4.71 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 6.46 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 36.0%
PRME is currently trading at $3.84, placing it 36.0% of the way from its 52-week low of $2.67 to its 52-week high of $5.91. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 146 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Prime Medicine, Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | Sep 10, 2019 |
| Payment Date | Sep 12, 2019 |
| Dividend Per Share | $0.8 |
Latest news related to Prime Medicine, Inc. and PRME stock.
HC Wainwright & Co. analyst Arthur He reiterates Prime Medicine (NASDAQ:PRME) with a Buy and maintains $8 price target.
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.25) by 12 percent. This is a 31.25 percent increase over losses of $(0.32) per share from the
Prime Medicine (PRME) reported a quarterly loss of $0.22 per share, beating consensus estimates of $0.23 loss by 4.35%, but missed revenue expectations with $4.21 million versus the consensus estimate, down 25.8%. The stock has outperformed the S&P 500 by 12.6% year-to-date but carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Absci Corporation (ABSI) reported a quarterly loss of $0.17 per share, missing the consensus estimate of $0.15 loss by 13.33%. Revenue came in at $0.3 million, significantly missing estimates by 88.43%. The company has failed to beat consensus estimates for four consecutive quarters. Despite a 190% year-to-date gain, ABSI received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Eligible investors can buy real shares of Prime Medicine, Inc. (PRME) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to PRME, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between PRME shares and USD.
PRME Shares to USD
1.00 PRME shares = 3.835 USD
Calculations are estimates based on the latest available price and are for reference only.